Ethylnitrosourea-induced mutation and molecular analysis of transgenic mice containing the gpt shuttle vector.
Novel transgenic mice were developed in order to study the in vivo mutagenesis. The transgenic mice carried pCGK shuttle vector, which contained the Escherichia coli gpt gene as a mutational target, the kanamycin-resistant gene (Kanr) and cos region derived from bacteriophage lambda. The shuttle vector can be recovered from the transgenic mouse genome into the gpt-deficient E. coli by an in vitro packaging method and is selectable as a Kanr phenotype. Mutations induced at the gpt gene can be easily detected with a selective agent, 6-thioguanine (6-TG). In the previous study, the pCGK shuttle vector was incorporated into Chinese hamster CHL/IU cells and the resultant transgenic cell line was shown to be a useful system to study in vitro mutagenesis at the gpt gene. Therefore, an advantage of the shuttle vector is that in vivo mutational data obtained from the transgenic mouse can be compared with those of transgenic cell line in vitro. A transgenic CD-1 mouse line, designated as #128, that carried approximately 50 copies of pCGK shuttle vectors, was selected among 4 transgenic mouse lines. To investigate the sensitivity of the #128 line, the transgenic mice were treated with a single intraperitoneal injection of 250 mg/kg of N-ethyl-N-nitrosourea (ENU) or with 50 mg kg-1 day-1 of ENU for 5 consecutive days, and bone marrow, spleen and liver were dissected to investigate their mutational responses. The background mutant frequency was between 18x10(-6) and 75x10(-6) among all tissues tested. ENU induced significant increases in the mutant frequency above the background level in all three tissues at 14 days after single or 5-day treatment with the chemical. The increases in the mutant frequencies in bone marrow, spleen and liver were 6.4- to 6.8-fold, 3.0- to 5.6-fold and 3.0- to 3.3-fold, respectively. The shuttle vector DNA was recovered from the bone marrow of both spontaneous and ENU-treated mice and the gpt gene was amplified by polymerase chain reaction. The amplified DNA was subject to DNA sequence analysis. Out of 79 spontaneous and 52 ENU-induced mutants, the gpt gene could be amplified from 28 spontaneous and 46 ENU-induced mutants. DNA sequence analysis showed that predominant mutations were identified as A:T to T:A transversions (22 out of 46 sequenced mutants) and G:C to A:T transitions (9/46) in ENU-induced mutants, whereas G:C to T:A transversions (7 out of 28 sequenced mutants) were predominant in spontaneous mutants. These results demonstrate that this transgenic mouse, in combination with the transgenic CHL/IU cell line, is a useful system to study in vivo and in vitro mutational events at the same target gene.
Yamada
T
T
Environmental Health Science Laboratory, Sumitomo Chemical, 1-98, 3-Chome, Kasugade-Naka, Konohana, Osaka 554-8558, Japan. yamadat9@sc.sumitomo-chem.co.jp
Yamamoto
R
R
Kaneko
H
H
Yoshitake
A
A
D019943:Amino Acid Substitution; D000818:Animals; D001426:Bacterial Proteins / Q000737:chemistry / Q000235:genetics*; D010582:Bacteriophage lambda / Q000235:genetics; D001854:Bone Marrow Cells / Q000187:drug effects / Q000473:pathology; D002460:Cell Line; D006224:Cricetinae; D003412:Cricetulus; D004926:Escherichia coli / Q000235:genetics; D029968:Escherichia coli Proteins; D005038:Ethylnitrosourea / Q000633:toxicity*; D005822:Genetic Vectors; D007613:Kanamycin Resistance / Q000235:genetics; D008099:Liver / Q000187:drug effects / Q000473:pathology; D051379:Mice; D008822:Mice, Transgenic; D009152:Mutagenicity Tests; D009153:Mutagens / Q000633:toxicity*; D010430:Pentosyltransferases; D017354:Point Mutation; D011506:Proteins; D017384:Sequence Deletion; D013154:Spleen / Q000187:drug effects / Q000473:pathology; D014162:Transfection
D001426:Bacterial Proteins; D029968:Escherichia coli Proteins; D009153:Mutagens; D011506:Proteins; D010430:Pentosyltransferases; C071962:Gpt protein, E coli; D005038:Ethylnitrosourea